<SEC-DOCUMENT>0001213900-26-032340.txt : 20260320
<SEC-HEADER>0001213900-26-032340.hdr.sgml : 20260320
<ACCEPTANCE-DATETIME>20260320160523
ACCESSION NUMBER:		0001213900-26-032340
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260320
DATE AS OF CHANGE:		20260320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286956
		FILM NUMBER:		26778250

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Enlivex Therapeutics Ltd.
		DATE OF NAME CHANGE:	20190326

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea028279301-424b3_enlivex.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Registration No. 333-286956</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(to Prospectus Dated May 12, 2025)<BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""><FONT STYLE="font-size: 12pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Up to $250,000,000 of Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus supplement updates
and amends certain information contained in the prospectus supplement, dated November 24, 2025, and the accompanying prospectus, dated
May 12, 2025 (together, the &ldquo;Prospectus&rdquo;), relating to the sale of our ordinary shares, par value NIS 0.40 per share (&ldquo;ordinary
shares&rdquo;), from time to time to or through BTIG, LLC (the &ldquo;Sales Agent&rdquo;), pursuant to that certain At-The-Market Sales
Agreement, dated November 24, 2025 (the &ldquo;Sales Agreement&rdquo;), by and between us and the Sales Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we elect to sell any ordinary
shares pursuant to&nbsp;this prospectus supplement and the Prospectus,&nbsp;such sales, if any, may be made in transactions that are deemed
to be &ldquo;at-the-market&rdquo; offerings as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus supplement should
be read in conjunction with the Prospectus and is qualified by reference to the Prospectus, except to the extent that the information
contained herein supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may only
be delivered or used in connection with, the Prospectus, including any other amendments or supplements thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the Prospectus, we initially
registered up to $299,553,108 of our ordinary shares for offer and sale pursuant to the Sales Agreement. From November 24, 2025 through
the date of this prospectus supplement, we have sold an aggregate of 1,936,660 ordinary shares for an aggregate gross sales price of $2,513,111
under the Prospectus. As of the date of this prospectus supplement, we are reducing the amount of our ordinary shares that we are offering
pursuant to the Sales Agreement and the Prospectus, as supplemented by this prospectus supplement, such that we are offering up to an
aggregate of $250,000,000 of our ordinary shares for sale under the Sales Agreement from and after the date hereof, excluding ordinary
shares previously sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ordinary shares are listed
on the Nasdaq Capital Market under the symbol &ldquo;ENLV&rdquo; and on the Tel Aviv Stock Exchange under the symbol &ldquo;ENLV.&rdquo;
The last reported sale price of our ordinary shares on the Nasdaq Capital Market on March 19, 2026 was $1.08 per share. The last reported
sale price of our ordinary shares on the Tel Aviv Stock Exchange on March 19, 2026 was NIS 3.4050 or $1.09170 per share (based on the
exchange rate reported by the Bank of Israel on the same day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a &ldquo;foreign private
issuer&rdquo; as defined under the U.S. federal securities laws and, as such, may elect to comply with certain reduced public company
disclosure and reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Investing in our securities
involves a high degree of risk. See the risks described in the &ldquo;Risk Factors&rdquo; sections of the Prospectus and in the reports
we file with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) pursuant to the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;), incorporated by reference into this prospectus supplement and the Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B>Neither the SEC, the Israel
Securities Authority nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or
adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BTIG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus supplement is March 20,
2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !B 4<# 2(  A$! Q$!_\0
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MI/AYX_ET^X8C3;H@;F/&PGY'_ \'_@5>QUEB:2A.\?A>J-\'6=2'+/XHZ/\
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MI_\ SX6O_?E?\*/[+T__ )\+7_ORO^%6Z*X^9]ST.2/8;'&D48CC140<!5&
M/PKR&8'X?_$H2CY-,O>OH(V//_?+?H/>O8*Y'XBZ!_;?AJ26),W5GF:/ Y(_
MB7\N?J!73A:B4^66TM&<F,I.5/GA\4=5_D=7+-'# \\CJL2*79R>  ,DUY+X
M:BD\;_$*XUNX4FRM&#HK=!CB-?TR?H?6LZ[\=277P]@T4,QORWD2GGF)<8_$
M\+^!]:]-\%: /#WAJWMG7%S)^]G/?>>WX# _"M^1X:G)OXGHO3JSF518RK!1
M^&.K]>B.AHHHKS3U@) !). *\6^TGQ?\0Y]0^]969_=YZ;5X3\SEOSKT;QWJ
M3:7X-U":,D2.@A4C_:.#^A-<3X*L1:>'HYB/WETQE8^W0?R_6O1PJY*<JG5Z
M+]3RL9+GJQI=%J_T.OTF-9=2C#<A<M^(JUKEU(;G[.&(C4 D#N36?97'V6[C
MFZ@'YA[=ZW-0T]=15+BWD7=CKV85A*RFFSH@FZ;4=S!MKB2UF62,D8/([$>E
M;.O1JUM#-CY@VW\"/_K5#::'+YJM<E0BG.U3DFDUR\65UMXSD(<L1Z^E#:E-
M6&DXTWS&11116QSA1110 $ @@@$'@@]Q7,>!)CH'Q!O=&+8@N00@/J!N0_ED
M?C73UQVLN;'XB:)=I]YVB#=OX]I_2MJ2YE*'=/\  YZSY'"HNC7XZ'M%%%%>
M2>X%>$N-</Q'U<>'R1??:)NFW[NXY^]Q7NU>3>%O^2PZM_UTN/\ T*N_!RY5
M4?E^IYF/CS2I1O:\OT%\OXJ?WW_."K%BGQ-&H6WVIW^S^:OF\P?=R,].>E>H
M45#Q=_L1^XT6"L[^TE]X5Y'X\_Y*EHWTM_\ T:U>N5Y'X\_Y*EHWTM__ $:U
M/ _Q'Z/\B<Q_@KU7YG5?$;PW_;F@FY@3-[9 R)@<LG\2_P!1]/>F?#;Q)_;6
MA"SN'S>60"-D\NG\)_H?H/6NUKQW6[>7X?>/8=4M4(TZZ8L47IM)^=/PZC\/
M2JH?OJ;HO=:K_(G$+V%58A;/27Z,G\&?\E:UC_?N?_1E=WXX_P"1*U7_ *X_
MU%<!X'FCN/BGJD\+AXI/M#HP[@N"#7?^./\ D2M5_P"N/]15XC_>(?\ ;IGA
MO]UJ>LOU,;X4?\B<W_7T_P#):[FN&^%'_(G-_P!?3_R6NYKEQ7\:7J=F"_W>
M'H%>2^*?^2Q:3_UTM_\ T*O6J\E\4_\ )8M)_P"NEO\ ^A5K@OCEZ,QS#^''
M_$OS/6J\H\=J= ^(.E:Z@Q'+M,A'<J=K?^.D5ZO7$?%+3/MOA,W*+F2SE63W
MVGY3_,'\*C"24:J3V>GWFF.@Y4&UNM5\C>\4ZF-*\*ZA>JX#"$B,_P"TWRK^
MI%<U\)M-^R^&YKYEP]Y,<'_87@?KNKF/$WB!M2^'GA^S1BTUP=L@'4^7\O/U
M)!KU;1=/72M$LK!<?N(50X[MCD_GFM:D71H<KW;_  1C3FJ^)4UM&*^^7_ &
M^(/^1;U3_KSE_P#0#7BWA%?&#6ES_P (VS"#S!YN/+^]CC[U>T^(/^1;U3_K
MSE_] -</\'O^03J7_7=?Y56'GR8><K7U6Y.*I^TQ5.-VM'L4/+^*G]]_S@K?
M\(KXW766_P"$A9C9>4V,^5]_(Q]WGUKN:*QGB>:+CR)?(Z(8/DDI<\G;S"F2
MR1PPO+*P6-%+,QZ #J:?7!?%+7SI^B)I<#8N+[AL=1&.OYGCZ9K&E3=2:@NI
MO7JJC3<WT/--+OM*B\=PWKP;=,^V%U0G[BY^4GV'!Q[5]$ Y&1TKRO4/ /D?
M#6/;%_Q-(,W<AQ\QR/F3\% _%?>ND^'/B#^VO#:0ROFZLL0R9/)7^$_EQ^!K
MOQG+5C[2'V=/^">9@%*A-TJBUDN9?JOD=A1117EGLG'?$^-Y/!%R5&0DD;-[
M#=C^HK#\+R++X8T\J?NQ;3]02#7H&KZ>FK:1=V$APL\3)GT)'!_ X->2>"+F
M2VEOM$N04F@D+JI[8.&'X'%>E0?-0<>SO]YY.)7)B5)[25OFCL:GM[RXM3^Y
ME*CN.H_*H**EJ^Y:;6Q<EU2\F3:TQ /7:,53HHI)); VWN%%%%,04444 %<;
MK&=5^(&D:?;_ #/"Z!\=OFW'\E&:W]>U=-%TN2Z(#2GY(4/\3G^@ZU)\,O#<
ML4<GB+4 6NKK/D[NH4]6^I[>WUK:#]G!U7Z+U,)Q=6I&C'U?DE_F>C4445Y)
M[85Y#X>N8+7XNZM)<31PIYEP-TCA1][U->O5P6I?"S3]3U2ZOI-0N4>XE:4J
MJK@$G.*Z\-.$5)3=KJQPXRG4FX2IJ[B[]CK_ .V]*_Z"=E_X$+_C1_;>E?\
M03LO_ A?\:X;_A3^F_\ 03N_^^5H_P"%/Z;_ -!.[_[Y6J]GAOYW]Q/M<9_S
M[7_@1Z#;WEM>*S6UQ#.JG!,3AL?E7E/CS_DJ6C?2W_\ 1K5WOA;PK;^%;:XA
MM[B6<3.&)D &,#VJOK7@JUUKQ%:ZS+=31RVX0*B@8.UBP_G2HSITJK=]+/\
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M3@<O(?O2-ZFM2BBO/E)R=WN>K&*BE&*LD%%%%24%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
